About: Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.00 (-3.85%)
OCGN NASDAQ Ocugen Inc
Ocugen Inc share price
OCGN price activity
Último preço
$ 1,000
Variação (24h)
-0,04 USD (-3,85%)
Volume
5.20M
Volume (média 4 sem.)
-
Abertura
$ 1,04
Variação do dia
$ 1,00 - $ 1,05
Fechamento anterior
$ 1,04
Último negócio
07 Oct, 8:25 pm GMT+0
Atrasado
07 Oct, 8:25 pm GMT+0
OCGN price performance
Atrasado
07 Oct, 8:25 pm GMT+0
quote.marketSignals